Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't care about the plane.You got a picture of the pilots just to make the KBIO plot more interesting...
SAW KBIO MOVING@7. WAS SCRATCHING MY HEAD..AND..IT..JUMPED..TO..$10.
Shoot...I would be...wouldn't you? lol
KBIO: Amateurs playing with the pps here...Lol
Shorts nightmare lol
" management is currently unable to coment on stock move " being too busy booking flights to Dubaï on a prototype futurist plane piloted by the prettiest girls in the world.
This is crazy lol
LOL!! I KNOW, RIGHT??!! DARN NO $20~ lolllll
Doesn't seems like it
Just insider brought over 50% of o/s
Graveyard. Just popped in jurassic park
Hehe 1 st shift or 2nd? ;)~
Tomorrow 40$ a share be ready ;) got
1000 at 12$ in after market will let
It
Go at 40 even 50$ :) I think everyone enjoy burning all those shorts hahahahah I DO !!!
Who was in this stock before the close? How many shares did you have? What price did you sell at?
Share your story!
14 minutes left to smack that Ask...otherwise, guess I will be seeing folks at 30!! Lolzzz
Just read post #700
They got Phase IIII approval. Provided FDA a pizza with 4 toppings...LOL.
Any idea why anyone ? Is it cause of pass of phase 2 ? If it is company worth 300 million plus asset ?
they are getting insiders out,, great mm fund controlling the float,,at some point they short it down when available myop
Omg plzzzzzz allow me to short this!
"A stock market tutorial."
Martin Shkreli Makes 1,080% On Penny Stock Days After Company Said It Would Shut Down
http://m.benzinga.com/article/5985493
So 500k shares were bought at .69 ? N they ready to sell those within a week for a gigantic profit? Wow dont wanna get traped here
Looks like you made out like a bandit here.
It should have tanked but dumb shorts didn't factor in the tiny float and ran out of shares to short and were forced to chase. Tiny floats are always fun!
Congrats ospreyeye
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43312
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |